Biohaven Pharmaceutical Holding Company Ltd.(BHVN) Stock Research - Grey Stern Research

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Stock Analysis

$28.66 (-4.05%)

BHVN Financial Performance


Use the table below to view Biohaven Pharmaceutical Holding Company Ltd.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q4 - 2024

Metric Value Ranking among Peers
Price $29.87 -
52 Week Low $26.80 -
52 Week High $59.53 -
Market Cap $3.0 Billion 5/17
Gross Margin 0% 11/17
Profit Margin 0% 2/17
EBITDA margin -100% 3/17
Q4 - 2024 Revenue $0 11/17
Q4 - 2024 Earnings -$186.8 Million 16/17
Q4 - 2024 Free Cash Flow -$170.8 Million 17/17
Trailing 4 Quarters Revenue $0 12/17
Trailing 4 Quarters Earnings -$846.4 Million 17/17
Quarterly Earnings Growth -29% 13/17
Annual Earnings Growth -87% 16/17
Quarterly Revenue Growth 0% 7/17
Annual Revenue Growth 0% 8/17
Cash On Hand $99.1 Million 13/17
Short Term Debt $3.8 Million 10/17
Long Term Debt $32.8 Million 10/17

Biohaven Pharmaceutical Holding Company Ltd. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Biohaven Pharmaceutical Holding Company Ltd.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE -1.00 4/17
PS -1.00 12/17
PB 7.20 4/17
PC 30.75 2/17
Liabilities to Equity 0.45 7/17
ROA -1.38 17/17
ROE -2.00 17/17
Current Ratio 3.21 11/17
Quick Ratio 2.54 11/17
Long Term Debt to Equity 0.08 8/17
Debt to Equity 0.09 8/17
Burn Rate 0.52 16/17
Cash to Cap 0.03 16/17
CCR 0.91 2/17
EV to EBITDA -1.00 3/17
EV to Revenue -1.00 11/17

Company Details

Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole for spinocerebellar ataxia and obsessive compulsive disorders, as well as Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000/5500 for neuropsychiatric indications; and Verdiperstat, a product for multiple system atrophy and amyotrophic lateral sclerosis. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was incorporated in 2013 and is headquartered in New Haven, Connecticut.

CEO: Mr. Vlad Coric

Website: https://www.biohavenpharma.com

Address: 215 Church St New Haven, CONNECTICUT

Exchange: New York Stock Exchange

Industry: Biotechnology

Biohaven Pharmaceutical Holding Company Ltd. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Biohaven Pharmaceutical Holding Company Ltd.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Mirati Therapeutics, Inc. MRTX $4.1 Billion
Blueprint Medicines Corporation BPMC $5.9 Billion
Agios Pharmaceuticals, Inc. AGIO $1.8 Billion
Apellis Pharmaceuticals, Inc. APLS $3.0 Billion
X4 Pharmaceuticals, Inc. XFOR $45.0 Million
Revolution Medicines, Inc. RVMD $7.1 Billion
Inozyme Pharma, Inc. INZY $62.4 Million
Nurix Therapeutics, Inc. NRIX $954.7 Million
C4 Therapeutics, Inc. CCCC $154.8 Million
Immunome, Inc. IMNM $604.3 Million
Cerevel Therapeutics Holdings, Inc. CERE $8.2 Billion
Inhibrx, Inc. INBX $205.8 Million
Kymera Therapeutics, Inc. KYMR $2.1 Billion
Terns Pharmaceuticals, Inc. TERN $289.8 Million
Day One Biopharmaceuticals, Inc. DAWN $839.2 Million
Icosavax, Inc. ICVX $769.0 Million
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
BHVN Income Statements
Quarter Year Revenue Earnings
Q4 2024 $ 0 -$186.8 Million
Q3 2024 $ 0 -$160.3 Million
Q2 2024 $ 0 -$319.8 Million
Q1 2024 $ 0 -$179.5 Million
Q4 2023 $ 0 -$144.8 Million
Q3 2023 $ 0 -$102.6 Million
Q2 2023 $ 0 -$90.3 Million
Q1 2023 $ 0 -$70.5 Million

View All

BHVN Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q4 2024 $99.1 Million $615.1 Million $36.6 Million $423.4 Million
Q3 2024 $84.4 Million $510.5 Million $25.3 Million $316.0 Million
Q2 2024 $239.3 Million $582.6 Million $29.7 Million $383.7 Million
Q1 2024 $184.5 Million $418.5 Million $30.5 Million $301.4 Million
Q4 2023 $249.7 Million $513.2 Million $30.9 Million $428.0 Million
Q3 2023 $111.7 Million $382.7 Million $28.3 Million $290.0 Million
Q2 2023 $147.6 Million $506.7 Million $29.1 Million $387.3 Million
Q1 2023 $125.0 Million $618.5 Million $29.8 Million $472.3 Million

View All

BHVN Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q4 2024 -$170.8 Million -$49,000 $14.5 Million
Q3 2024 -$141.9 Million -$611,000 -$151.3 Million
Q2 2024 -$170.7 Million -$2.9 Million $54.8 Million
Q1 2024 -$103.1 Million -$440,000 -$65.2 Million
Q4 2023 -$115.4 Million -$470,000 $126.1 Million
Q3 2023 $15.7 Million $0 $127.5 Million
Q2 2023 -$45.0 Million -$595,000 $11.4 Million
Q1 2023 -$78.4 Million -$735,000 -$52.0 Million

View All

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions